Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products, through its contract development and manufacturing organization (“CDMO”) business unit, Scinai Bioservices, has signed a five-year Master Service Agreement (“MSA”) with Ayana Pharma Ltd. As outlined by the MSA, Scinai will provide drug-development and cGMP manufacturing services to Ayana; the agreement is forecast to bring in at least $1.8 million in revenues for Scinai over the next five years. Ayana officials noted that the company had done an extensive search looking for a CDMO and was “attracted” to Scinai’s experience in biopharmaceutical drug development and manufacturing for clinical trials as well as its customer responsiveness and track record for meeting stringent international regulatory requirements. Company officials also appreciated the pristine condition of Scinai’s modern and highly equipped laboratories and clean rooms. “This five-year contract validates our strategic decision to create two business units, one focused on providing CDMO services and the other on drug development of an innovative pipeline of biologic therapeutic products under license from the Max Planck Society and the University Medical Center Gottingen, Germany,” said Scinai Immunotherapeutics CEO Amir Reichman in the press release. “This important CDMO contract with Ayana joins additional contracts already signed with other clients by our CDMO unit, all of which are generating revenues, offsetting fixed costs and allowing for rapid growth of our business.”
To view the full press release, visit https://ibn.fm/dKBNA
About Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics is a biopharmaceutical company with two complementary business units: one focused on in-house development of inflammation and immunology (“I&I”) biological products beginning with an innovative, derisked pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO (“CDMO”) providing biological drug development, analytical methods development, clinical GMP manufacturing, and preclinical and clinical trial design and execution services to early-stage biotech companies. For more information, visit the company’s website at www.Scinai.com.
NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]
InvestorWire is powered by IBN